{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T23:26:49Z","timestamp":1775863609748,"version":"3.50.1"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Triple-negative breast cancer (TNBC) is a heterogeneous disease with subtypes having different \u201ctargetable\u201d molecular aberrations. Metaplastic breast cancers (MpBCs) are typically TNBCs and commonly have alterations in the PI3K\/Akt\/mTOR pathway. We previously reported efficacy for an mTOR-based chemotherapy regimen in MpBC. To determine if tumor subtype influences prognosis, we compared treatment outcomes of patients with MpBC with those of patients with nonmetaplastic TNBC receiving an mTOR-based systemic therapy regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>Patients with advanced MpBC and nonmetaplastic TNBC were treated at our institution from April 16, 2009, through November 4, 2014, using mTOR inhibition (temsirolimus or everolimus) with liposomal doxorubicin and bevacizumab (DAT\/DAE). Median progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method. Cox regression analyses were used to evaluate associations between tumor histology and outcomes. Multivariable models were adjusted for all covariates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fourteen patients with nonmetaplastic TNBC and 59 patients with advanced MpBC were treated with DAT\/DAE. MpBC patients were older (p = .002) and less likely to have a history of bevacizumab use (p = .023). Median PFS for the nonmetaplastic TNBC and MpBC patients was 2.5 months and 4.8 months, respectively. This difference in PFS was statistically significant on univariable (p = .006) but not multivariable analysis (p = .087). Median OS for the nonmetaplastic TNBC and MpBC patients was 3.7 months and 10.0 months, respectively (p = .0003). MpBC remained significantly associated with improved OS on multivariable analysis (p &amp;lt; .0001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In our study, DAT\/DAE appeared to be more effective in MpBC compared with nonmetaplastic TNBC. These data support patient selection for targeted therapy in TNBC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Metaplastic breast cancers (MpBCs) represent &amp;lt;1% of all breast cancers, demonstrate mesenchymal differentiation, and are typically resistant to chemotherapy. Patients with advanced MpBC treated with an mTOR-based systemic therapy regimen had better long-term outcomes compared with patients with nonmetaplastic triple-negative breast cancer treated with the same regimen, suggesting that metaplastic histology may predict benefit from agents targeting the PI3K\/Akt\/mTOR pathway.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0498","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T15:05:14Z","timestamp":1535036714000},"page":"1300-1309","source":"Crossref","is-referenced-by-count":56,"title":["Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer"],"prefix":"10.1093","volume":"23","author":[{"given":"Reva K.","family":"Basho","sequence":"first","affiliation":[{"name":"Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clinton","family":"Yam","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gilcrease","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi K.","family":"Murthy","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorunn","family":"Helgason","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D.","family":"Karp","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth R.","family":"Hess","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Albarracin","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer K.","family":"Litton","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Chavez-MacGregor","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Division of Hematology and Oncology, The University of California San Diego Moores Cancer Center, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy L.","family":"Moulder","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,8,23]]},"reference":[{"key":"2021122511252294500_onco12677-bib-0001","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1136\/jcp.2005.030536","article-title":"Metaplastic carcinoma of the breast: A clinicopathological review","volume":"59","author":"Tse","year":"2006","journal-title":"J Clin Pathol"},{"key":"2021122511252294500_onco12677-bib-0002","first-page":"628","article-title":"Metaplastic carcinomas of the breast","volume":"20","author":"Wargotz","year":"1989","journal-title":"I. Matrix-producing carcinoma. Hum Pathol"},{"key":"2021122511252294500_onco12677-bib-0003","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/0046-8177(89)90065-8","article-title":"Metaplastic carcinomas of the breast. II. Spindle cell carcinoma","volume":"20","author":"Wargotz","year":"1989","journal-title":"Hum Pathol"},{"key":"2021122511252294500_onco12677-bib-0004","first-page":"1490","article-title":"Metaplastic carcinomas of the breast","volume":"64","author":"Wargotz","year":"1989","journal-title":"III. Carcinosarcoma. Cancer"},{"key":"2021122511252294500_onco12677-bib-0005","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/1097-0142(19900115)65:2<272::AID-CNCR2820650215>3.0.CO;2-6","article-title":"Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin","volume":"65","author":"Wargotz","year":"1990","journal-title":"Cancer"},{"key":"2021122511252294500_onco12677-bib-0006","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/0046-8177(90)90151-T","article-title":"Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells","volume":"21","author":"Wargotz","year":"1990","journal-title":"Hum Pathol"},{"key":"2021122511252294500_onco12677-bib-0007","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11912-014-0431-z","article-title":"Metaplastic breast cancer: Clinical overview and molecular aberrations for potential targeted therapy","volume":"17","author":"Abouharb","year":"2015","journal-title":"Curr Oncol Rep"},{"key":"2021122511252294500_onco12677-bib-0008","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1008329910362","article-title":"Metaplastic breast cancer: Prognosis and response to systemic therapy","volume":"10","author":"Rayson","year":"1999","journal-title":"Ann Oncol"},{"key":"2021122511252294500_onco12677-bib-0009","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-0780-8","article-title":"Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer","volume":"120","author":"Jung","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"2021122511252294500_onco12677-bib-0010","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"2021122511252294500_onco12677-bib-0011","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1158\/0008-5472.CAN-08-3441","article-title":"Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics","volume":"69","author":"Hennessy","year":"2009","journal-title":"Cancer Res"},{"key":"2021122511252294500_onco12677-bib-0012","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122511252294500_onco12677-bib-0013","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes","volume":"19","author":"Masuda","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2021122511252294500_onco12677-bib-0014","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/jamaoncol.2016.5281","article-title":"Targeting the PI3k\/Akt\/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: Evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab","volume":"3","author":"Basho","year":"2017","journal-title":"JAMA Oncol"},{"key":"2021122511252294500_onco12677-bib-0015","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1158\/1078-0432.CCR-12-1158","article-title":"Phase I study of the antiangiogenic antibody bevacizumab and the mTOR\/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: Tolerance and biological activity","volume":"18","author":"Moroney","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122511252294500_onco12677-bib-0016","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdv163","article-title":"Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer","volume":"26","author":"Moulder","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122511252294500_onco12677-bib-0017","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1200\/JCO.2010.34.0604","article-title":"Responses to liposomal doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: Biologic rationale and implications for stem-cell research in breast cancer","volume":"29","author":"Moulder","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122511252294500_onco12677-bib-0018","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.1158\/1078-0432.CCR-11-0666","article-title":"A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies","volume":"17","author":"Moroney","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122511252294500_onco12677-bib-0019","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000350774","article-title":"A brief overview of the WHO Classification of Breast Tumors, 4th edition, focusing on issues and updates from the 3rd edition","volume":"8","author":"Sinn","year":"2013","journal-title":"Breast Care (Basel)"},{"key":"2021122511252294500_onco12677-bib-0020","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor. receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122511252294500_onco12677-bib-0021","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J. Cancer"},{"key":"2021122511252294500_onco12677-bib-0022","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1634\/theoncologist.2017-0095","article-title":"Targeting the molecular subtypes of triple negative breast cancer: Understanding the diversity to progress the field","volume":"22","author":"Yam","year":"2017","journal-title":"The Oncologist"},{"key":"2021122511252294500_onco12677-bib-0023","doi-asserted-by":"crossref","first-page":"13820","DOI":"10.1073\/pnas.0905718106","article-title":"Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features","volume":"106","author":"Creighton","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122511252294500_onco12677-bib-0024","first-page":"669","article-title":"Metaplastic breast carcinoma: Pathology and clinical outcome","volume":"23","author":"Bellino","year":"2003","journal-title":"Anticancer Res"},{"key":"2021122511252294500_onco12677-bib-0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1075-122X.2005.00031.x","article-title":"Metaplastic breast carcinoma with squamous differentiation: Molecular and clinical analysis of six cases","volume":"11","author":"Kochhar","year":"2005","journal-title":"Breast J"},{"key":"2021122511252294500_onco12677-bib-0026","doi-asserted-by":"crossref","first-page":"16158","DOI":"10.1073\/pnas.0702596104","article-title":"Activation of the PTEN\/mTOR\/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance","volume":"104","author":"Zhou","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122511252294500_onco12677-bib-0027","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1158\/0008-5472.CAN-05-3830","article-title":"Survival signaling by Notch1: Mammalian target of rapamycin (mTOR)-dependent inhibition of p 53","volume":"66","author":"Mungamuri","year":"2006","journal-title":"Cancer Res"},{"key":"2021122511252294500_onco12677-bib-0028","first-page":"4641","article-title":"Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: Exploiting the hypoxia-induced pathway","volume":"9","author":"Pantuck","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122511252294500_onco12677-bib-0029","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","article-title":"Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus","volume":"66","author":"Del Bufalo","year":"2006","journal-title":"Cancer Res"},{"key":"2021122511252294500_onco12677-bib-0030","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1158\/1535-7163.MCT-07-0237","article-title":"Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer","volume":"6","author":"Huynh","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"2021122511252294500_onco12677-bib-0031","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jhep.2008.02.022","article-title":"Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma","volume":"49","author":"Huynh","year":"2008","journal-title":"J Hepatol"},{"key":"2021122511252294500_onco12677-bib-0032","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10549-011-1359-8","article-title":"The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients","volume":"126","author":"Bae","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2021122511252294500_onco12677-bib-0033","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.humpath.2009.11.013","article-title":"Metaplastic carcinoma of the breast","volume":"41","author":"Okada","year":"2010","journal-title":"Hum Pathol"},{"key":"2021122511252294500_onco12677-bib-0034","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2021122511252294500_onco12677-bib-0035","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/annonc\/mdw665","article-title":"Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer","volume":"28","author":"Bell","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122511252294500_onco12677-bib-0036","doi-asserted-by":"crossref","first-page":"15746","DOI":"10.1038\/srep15746","article-title":"Efficacy and safety of bevacizumab combined with chemotherapy for managing metastatic breast cancer: A meta-analysis of randomized controlled trials","volume":"5","author":"Li","year":"2015","journal-title":"Sci Rep"},{"key":"2021122511252294500_onco12677-bib-0037","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ctrv.2014.05.006","article-title":"A systematic review of bevacizumab efficacy in breast cancer","volume":"40","author":"Kumler","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"2021122511252294500_onco12677-bib-0038","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/1097-0142(19801201)46:11<2380::AID-CNCR2820461113>3.0.CO;2-M","article-title":"Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy","volume":"46","author":"Nash","year":"1980","journal-title":"Cancer"},{"issue":"suppl 5","key":"2021122511252294500_onco12677-bib-0039","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3109\/02841869609083978","article-title":"Predictive factors for response to cytotoxic treatment in advanced breast cancer: A review","volume":"35","author":"Sjostrom","year":"1996","journal-title":"Acta Oncol"},{"key":"2021122511252294500_onco12677-bib-0040","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/S0959-8049(00)00325-7","article-title":"Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer","volume":"36","author":"Robain","year":"2000","journal-title":"Eur J. Cancer"},{"key":"2021122511252294500_onco12677-bib-0041","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q","article-title":"Evaluation of patients with advanced cancer using the Karnofsky performance status","volume":"45","author":"Yates","year":"1980","journal-title":"Cancer"},{"key":"2021122511252294500_onco12677-bib-0042","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdr444","article-title":"A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer","volume":"23","author":"Aogi","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122511252294500_onco12677-bib-0043","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.breast.2016.12.017","article-title":"Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes","volume":"32","author":"Maeda","year":"2017","journal-title":"Breast"},{"key":"2021122511252294500_onco12677-bib-0044","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/sj.bjc.6605961","article-title":"Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: A pooled analysis using individual data from four prospective trials","volume":"103","author":"Al-Batran","year":"2010","journal-title":"Br J. Cancer"},{"key":"2021122511252294500_onco12677-bib-0045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/5289","article-title":"Cancer multidrug resistance","volume":"17","author":"Persidis","year":"1999","journal-title":"Nat Biotechnol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0498","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0498","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/11\/1300\/41914640\/oncolo_23_11_1300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/11\/1300\/41914640\/oncolo_23_11_1300.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:27:14Z","timestamp":1640431634000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/11\/1300\/6439822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,23]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,8,23]]},"published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0498","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11,1]]},"published":{"date-parts":[[2018,8,23]]}}}